Grufity logo
Grufity logo

Latest Paradigm Biocapital Advisors LP Stock Portfolio

$4.89Billion | No. of Holdings #35

Paradigm Biocapital Advisors LP Performance

2026 Q1+11.48%
YTD+11.48%
2025+33.45%

About Paradigm Biocapital Advisors LP and 13F Hedge Fund Stock Holdings

On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Paradigm Biocapital Advisors LP reported an equity portfolio of $4.9 Billions as of 31 Mar, 2026. <br><br> The top stock holdings of Paradigm Biocapital Advisors LP are ACLX, RVMD, NUVL. The fund has invested 13.6% of it's portfolio in ARCELLX INC and 13.2% of portfolio in REVOLUTION MEDICINES INC . <br><br> The fund managers got completely rid off CIDARA THERAPEUTICS INC (CDTX), CRINETICS PHARMACEUTICALS IN (CRNX) and BRIDGEBIO PHARMA INC (BBIO) stocks. They significantly reduced their stock positions in UROGEN PHARMA LTD (URGN), BRIDGEBIO ONCOLOGY THERAPEUT and SCHOLAR ROCK HLDG CORP (SRRK). Paradigm Biocapital Advisors LP opened new stock positions in INSMED INC (INSM), BELITE BIO INC (BLTE) and CENTESSA PHARMACEUTICALS PLC (CNTA). The fund showed a lot of confidence in some stocks as they added substantially to TERNS PHARMACEUTICALS INC (TERN), VIRIDIAN THERAPEUTICS INC (VRDN) and ORUKA THERAPEUTICS INC.
Paradigm Biocapital Advisors LP Equity Portfolio Value
Last Reported on: 15 May, 2026
$4.89Billion
  as of May 15, 2026

Paradigm Biocapital Advisors LP Annual Return Estimates Vs S&P 500

Our best estimate is that Paradigm Biocapital Advisors LP made a return of 11.48% in the last quarter. In trailing 12 months, it's portfolio return was 75.06%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
insmed inc 205,134,000
belite bio inc 177,741,000
centessa pharmaceuticals plc141,961,000
cytokinetics inc 97,603,300
tango therapeutics inc 83,882,500
maze therapeutics inc 81,920,300
tyra biosciences inc 78,706,200
mirum pharmaceuticals inc 57,737,500
New stocks bought by Paradigm Biocapital Advisors LP

Additions

Ticker% Inc.
terns pharmaceuticals inc 173
viridian therapeutics inc 118
oruka therapeutics inc 35.67
spyre therapeutics inc 33.4
lexeo therapeutics inc 29.83
apogee therapeutics inc 20.03
vaxcyte inc 17.82
genmab a/s 13.18
Additions to existing portfolio by Paradigm Biocapital Advisors LP

Reductions

Ticker% Reduced
urogen pharma ltd -61.91
bridgebio oncology therapeut-61.61
scholar rock hldg corp -59.96
abivax sa -45.5
oric pharmaceuticals inc -29.15
erasca inc -26.6
eyepoint inc -14.87
Paradigm Biocapital Advisors LP reduced stake in above stock

Sold off

Ticker$ Sold
ocular therapeutix inc -35,634,300
crinetics pharmaceuticals in-102,912,000
cidara therapeutics inc -167,780,000
bridgebio pharma inc -52,340,300
Paradigm Biocapital Advisors LP got rid off the above stocks

Sector Distribution

Paradigm Biocapital Advisors LP has about 81.3% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare81.3
Others18.7

Market Cap. Distribution

Paradigm Biocapital Advisors LP has about 17.4% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • UNALLOCATED
  • LARGE-CAP
  • SMALL-CAP
Category%
MID-CAP55.2
UNALLOCATED18.7
LARGE-CAP17.4
SMALL-CAP8

Stocks belong to which Index?

About 76% of the stocks held by Paradigm Biocapital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
Index%
RUSSELL 200076
Others24
Top 5 Winners (%)%
ERAS
erasca inc
290.4 %
ACLX
arcellx inc
75.5 %
oruka therapeutics inc
49.7 %
ORIC
oric pharmaceuticals inc
46.9 %
AGLE
spyre therapeutics inc
44.2 %
Top 5 Winners ($)$
ACLX
arcellx inc
285.3 M
ERAS
erasca inc
153.0 M
RVMD
revolution medicines inc
117.0 M
PCVX
vaxcyte inc
53.0 M
EWTX
edgewise therapeutics inc
46.5 M
Top 5 Losers (%)%
OLMA
olema pharmaceuticals inc
-39.6 %
lexeo therapeutics inc
-39.3 %
kalaris therapeutics inc
-31.6 %
VRDN
viridian therapeutics inc
-30.1 %
EYPT
eyepoint inc
-27.3 %
Top 5 Losers ($)$
OLMA
olema pharmaceuticals inc
-78.5 M
TARS
tarsus pharmaceuticals inc
-30.1 M
GMAB
genmab a/s
-29.8 M
VRDN
viridian therapeutics inc
-26.5 M
abivax sa
-25.7 M

Paradigm Biocapital Advisors LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Paradigm Biocapital Advisors LP

Paradigm Biocapital Advisors LP has 35 stocks in it's portfolio. About 67.6% of the portfolio is in top 10 stocks. OLMA proved to be the most loss making stock for the portfolio. ACLX was the most profitable stock for Paradigm Biocapital Advisors LP last quarter.

$4.89BTotal Value
39.00Positions
15 May, 2026Last Reported
Current holdings of Current Stock Holdings of Paradigm Biocapital Advisors LP, last reported on 15 May, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
BLTE
Belite Bio Inc

Belite Bio Inc

BLTE
Paradigm Biocapital Advisors LP's holding in Belite Bio Inc over time
3.63%1,114,780
$177.74M
3.63%
new position
GMAB
Genmab A/S

Genmab A/S

GMAB
Paradigm Biocapital Advisors LP's holding in Genmab A/S over time
4.37%7,967,840
$213.78M
4.37%
increased 13.18 percentadded
IVA
Inventiva Sa

Inventiva Sa

IVA
Paradigm Biocapital Advisors LP's holding in Inventiva Sa over time
0.45%4,000,000
$22.20M
0.45%
unchanged 0 percentunchanged